Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

CVS will be the first retailer to offer Nutrition 21's Diachrome nutrient-based insulin sensitizer for type 2 diabetes, the firm announces Feb. 22. "We believe Diachrome is a very promising product that addresses a healthcare crisis in the United States and worldwide and has significant market potential," Nutrition 21 COO Paul Intlekofer said, noting that the results of a 447-subject study on the safety and efficacy of Diachrome are to be published this summer. In addition, an economic analysis by Thomas Jefferson University shows that widespread use of Diachrome "could deliver significant health care savings" in the U.S. Efficacy and cost savings should encourage healthcare stakeholders to incorporate Diachrome into their treatment protocols." The move to CVS expands the firm's mass market presence: in January, Rite-Aid became the first retailer to carry the chromium picolinate supplement Chromax (1"The Tan Sheet" Jan. 23, 2006, In Brief)...

Related Content

Nutrition 21 Expands Into Cardiovascular Area With Iceland Health Buy
Chromax hits retail stores





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts